Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Fenofibrate
Drug ID BADD_D00873
Description Fenofibrate is a fibric acid derivative like [clofibrate] and [gemfibrozil].[A185954] Fenofibrate is used to treat primary hypercholesterolemia, mixed dyslipidemia, severe hypertriglyceridemia.[L8588,L8591] Fenofibrate was granted FDA approval on 31 December 1993.[L8585]
Indications and Usage Fenofibrate is indicated as adjunctive therapy to diet to reduce elevated LDL-C, Total-C, Triglycerides, and Apo B, and to increase HDL-C adults with primary hypercholesterolemia or mixed dyslipidemia.[L8588,L8591] Fenofibrate is also indicated to treat adults with severe hypertriglyceridemia.[L8588,L8591]
Marketing Status approved
ATC Code C10AB05
DrugBank ID DB01039
KEGG ID D00565
MeSH ID D011345
PubChem ID 3339
TTD Drug ID D07XGR
NDC Product Code 11014-0132; 11722-065; 17337-0019; 58175-0348; 0074-3173; 13668-439; 31722-595; 0115-5522; 42385-950; 50090-6227; 51079-599; 55111-349; 60505-3121; 60687-629; 60760-318; 62332-361; 62332-538; 63304-444; 68180-131; 68180-231; 68462-580; 68462-582; 69238-1263; 71205-050; 71205-190; 71205-666; 71205-949; 0904-7161; 66064-1006; 16714-740; 27437-109; 0115-0522; 0115-5511; 42385-951; 42858-200; 43547-431; 50090-3044; 63304-448; 68071-1712; 70518-2768; 71335-1701; 72789-310; 13668-440; 46708-085; 51407-092; 51407-204; 51655-234; 59651-203; 60687-666; 63187-640; 63304-901; 0378-7100; 68180-389; 68788-8106; 69844-008; 71335-1286; 71335-1292; 71335-2016; 59651-576; 60219-5522; 62332-086; 62332-554; 62559-305; 63187-940; 63304-449; 0378-4391; 68462-581; 69097-894; 69238-1261; 69367-270; 70756-214; 71205-366; 71335-0741; 71335-0891; 82009-060; 11014-0131; 17337-0410; 27437-110; 35561-345; 42291-289; 42385-936; 42858-454; 42858-660; 43975-306; 46708-555; 51407-205; 59651-201; 60687-713; 62332-084; 63187-681; 0378-3066; 68071-2587; 68180-746; 68682-490; 69238-1260; 69315-290; 69367-254; 69844-013; 46708-084; 46708-361; 46708-554; 50268-312; 50268-338; 55700-876; 60219-5511; 60687-655; 62332-360; 62559-461; 68071-2812; 68788-7816; 69097-458; 69367-269; 69844-009; 70518-2349; 0615-8270; 65862-768; 68294-0001; 16714-741; 27241-120; 31722-596; 35561-346; 0115-0511; 42385-935; 42858-067; 46708-086; 46708-350; 46708-360; 50090-6120; 51407-094; 51655-433; 51655-856; 62332-539; 63304-443; 63629-1100; 63629-1101; 63629-9474; 0378-4390; 65862-769; 68071-2540; 68071-2686; 68788-7932; 69097-895; 69844-012; 17337-0430; 0904-7128; 59349-0018; 65977-0074; 16714-739; 35561-347; 0115-0533; 42291-427; 43353-001; 43353-272; 50090-1275; 50090-4698; 50090-5854; 51079-608; 59651-202; 62559-306; 63187-760; 63304-900; 0378-7101; 68012-490; 68084-328; 68180-232; 68180-388; 69315-288; 70934-977; 13672-020; 53747-033; 70966-0021; 13668-438; 27241-117; 27437-108; 42291-290; 43975-305; 43975-444; 51407-091; 60505-3120; 60687-618; 62332-085; 62332-351; 62559-460; 63629-7213; 0378-3065; 68084-827; 68180-130; 69097-896; 69315-287; 69367-268; 70518-2907; 70518-2947; 70518-3370; 71335-0872; 71610-027; 0074-3189; 27241-116; 27241-119; 43353-898; 43598-910; 50090-5244; 51407-090; 55111-395; 62332-350; 62332-555; 63629-1099; 63629-2505; 68012-495; 68084-329; 68682-495; 69097-459; 69238-1262; 69315-289; 70756-215; 71335-1756; 49452-3101; 68543-3173; 68543-3189; 27241-118; 42858-134; 43547-430; 43598-909; 46708-351; 50090-2899; 50090-5796; 50268-313; 51407-093; 51655-009; 51655-554; 59651-575
UNII U202363UOS
Synonyms Fenofibrate | Phenofibrate | Procetofene | Procetofen | Apo-Feno-Micro | Apo Feno Micro | Apo-Fenofibrate | Apo Fenofibrate | CiL | Controlip | durafenat | Fenobeta | Fenofanton | Fenofibrat AbZ | Fenofibrat AL | Fenofibrat AZU | AZU, Fenofibrat | Fenofibrat Heumann | Heumann, Fenofibrat | Fenofibrat Hexal | Hexal, Fenofibrat | Fenofibrat Stada | Stada, Fenofibrat | fenofibrat von ct | Fenofibrat-ratiopharm | Fenofibrat ratiopharm | Fénofibrate MSD | Gen-Fenofibrate | Gen Fenofibrate | LF-178 | LF 178 | LF178 | Lipanthyl | Lipantil | Fenofibrat FPh | Lipidil | Secalip | Supralip | Fénofibrate Debat | Debat, Fénofibrate | Lipidil-Ter | Lipidil Ter | Liparison | Livesan | Lofibra | MTW-Fenofibrat | MTW Fenofibrat | Novo-Fenofibrate | Novo Fenofibrate | Nu-Fenofibrate | Nu Fenofibrate | PMS-Fenofibrate Micro | PMS Fenofibrate Micro | Tricor | Normalip | Antara Micronized Procetofen | Micronized Procetofen, Antara | Procetofen, Antara Micronized
Chemical Information
Molecular Formula C20H21ClO4
CAS Registry Number 49562-28-9
SMILES CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Tenosynovitis15.07.01.004--Not Available
Tension19.06.02.005--Not Available
Therapeutic response decreased08.06.01.0160.000039%Not Available
Thrombocytopenia01.08.01.002--Not Available
Tongue oedema23.04.01.009; 10.01.05.008; 07.14.02.0070.000039%Not Available
Tooth disorder07.09.05.001--Not Available
Unintended pregnancy18.08.01.001--Not Available
Upper respiratory tract infection22.07.03.011; 11.01.13.009--
Urinary tract infection11.01.14.004; 20.08.02.001--
Urticaria23.04.02.001; 10.01.06.0010.000391%
Varicose vein24.10.04.001--Not Available
Vasodilatation24.03.02.003; 23.06.05.006--Not Available
Venous thrombosis24.01.01.0080.000039%Not Available
Ventricular extrasystoles02.03.04.007--Not Available
Vertigo04.04.01.003; 17.02.12.0020.000146%
Vision blurred06.02.06.007; 17.17.01.010--
Visual acuity reduced06.02.10.012; 17.17.01.0110.000039%
Visual impairment06.02.10.013--Not Available
Vomiting07.01.07.003--
Vulvovaginal candidiasis21.14.02.003; 11.03.03.005--Not Available
Weight decreased13.15.01.005--
Weight increased13.15.01.006--
White blood cell count decreased13.01.06.012--
Acute generalised exanthematous pustulosis23.03.10.002; 12.03.01.005; 11.07.01.018; 10.01.01.0340.000059%Not Available
Deep vein thrombosis24.01.02.003--Not Available
Hyperviscosity syndrome01.05.01.0160.000059%Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Lymphatic disorder01.09.01.003--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Skin burning sensation23.03.03.021; 17.02.06.0090.000079%Not Available
The 9th Page    First    Pre   9 10 11    Next   Last    Total 11 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene